Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the ...

Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Panelists discuss how thrombotic risk assessment—anchored in age, thrombotic history, and additional factors like leukocytosis and JAK2 allele burden—guides personalized therapy in polycythemia vera ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial ...

Incyte Corp (INCY) reports a 20% revenue increase, driven by strong Jakafi sales and a successful Niktimvo launch, while ...

Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results.

Discover key insights from Incyte's Q1 2025 earnings: robust revenue growth, Jakafi success, new product launches, and pipeline updates driving ...

Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

Incyte Corp raised the annual sales forecast for its blood cancer drug Jakafi on Tuesday, and said it expects minimal impact from U.S. tariffs due to its flexibility in sourcing supplies. CEO Hervé ...